Voisin Consulting Life Sciences (VCLS)’s Post

The latest BHI Weekly E-Newsletter is live! 🔬 ARPA-H Takes on Rare Diseases: ARPA-H’s latest project aims to deliver hope and improved outcomes to millions of Americans with rare diseases. 💡 TEDCO Invests in Sonogen Medical Inc.: TEDCO announced a $200,000 investment in Sonogen Medical, a company developing ultrasonic bone fracture healing technology. This investment will propel their research towards an efficient, cost-effective solution. 👩⚕️ Women's Health Innovation Summit USA: Join ARPA-H Director Renee Wegrzyn, PhD, and other leaders to learn about the new $100M ARPA-H Sprint for Women’s Health Program and the White House Initiative on Women’s Health Research plans. 💰 BiomX Inc Announces Merger Agreement with Adaptive Phage Therapeutics: BiomX's merger with Adaptive Phage Therapeutics will create a phage therapy company with an advanced pipeline, backed by a $50 million financing. 🚀 Virginia Commonwealth University’s Startup Accelerator to Propel University Research: Virginia Commonwealth University launched its first formal Startup Accelerator program to fast-track emerging companies based on university research with market potential. 🌐 Council on Strategic Risks: National Security and Pharmaceutical Ingredients: The COVID-19 pandemic has highlighted the need for secure pharmaceutical supply chains. The Council on Strategic Risks explores the national security imperative to address overreliance on imports for active pharmaceutical ingredients. Visit https://lnkd.in/e3K8pRi8 to read more.

Humans host a large number of commensal microbes - mainly bacteria - that live in our bodies in a largely benign or symbiotically beneficial manner. The largest number - of the order of 100 trillion - of such microbes reside in our gut, forming the gut microbiome ecosystem. A relatively smaller number, about a trillion, live in the various layers and regions of our skin and our scalp. The TOTAL number of human cells in an adult is somewhere within this range. In that sense, what we eat and what we apply on our external surfaces plays a very significant role in our well-being. In recent decades, the role of these gut and skin microbiomes in metabolic regulation and causality of disorders and diseases - including obesity and cancer - has been the subject of widespread research. Also - the gut-skin axis - meaning the influence of microbiomes in our alimentary canal on those in the dermal region, and vice versa - has emerged as a core area of interest in metabolic regulation, biochemistry and physiology. As each regional population - and, indeed, each one of us - has a unique genetic descriptor and a unique but constantly-in-flux microbiome profile, it follows logically that we cannot have a one-size-fits-all approach to personal care or nutraceutical interventions in management of our well-being. Wouldn't it be nice if we could understand how the products we apply on your skin or hair might affect our microbiome, especially our friendly commensal microbiota? Am looking forward to being at the session with Hedy Scheck of MyMicrobiome - The microbiome company and Vimal LifeSciences Pvt. Ltd. next month. #microbiome #personalcare #beautyandwellness

We're thrilled to be a sponsor for the Pharmabiotics 2024 event happening in Lille this March. Our very own Barry Skillington, straight-shooter and Chief Commercial Officer, will be there in person. If you've got questions or just want to chat about the latest in clinical trials, Barry's excited to chat with you all. Let's talk microbiome. It's more than just a buzzword – it's reshaping our understanding of health and how we tackle diseases. The path to turning this science into real treatments isn't always clear cut though. From the early stages of lab work to the final validation and commercialisation stages, challenges abound. But, so to do opportunities! A recent poll we ran showed that 46% of respondents believe microbiome clinical trials will see the most growth over the next five years. Clearly, there's a lot to talk about! So, are you as pumped about this as we are? Want to dive deeper into microbiome research or just curious about what's next? Barry would love to meet you at the event. Drop by our spot or book a meeting with him. Let's explore where this journey can take us, together. Book a meeting with Barry: https://hubs.la/Q02mm40p0 See you in Lille this March! Let's make it a meet-up to remember. #Pharmabiotics2024 #InnovationInHealthcare #TeamAtlantia

I'm excited to share my latest white paper on a topic I’m deeply passionate about: "Global Strategies for the Commercialization of Rare and Ultra-Rare Disease Therapies." authored in collaboration with Ini Umoh, Abdulhafeez Mustapha, B. Pharm, MBA, MPH and Yusuff Sodiq. Rare diseases present unique challenges—especially in LMICs, where infrastructure, access, and resources often fall short. In this paper, we explore how Pharma companies and global health partners can work together to bring life-saving therapies to underserved regions. Key takeaways include the importance of innovative pricing models, agile supply chains, and leveraging real-world evidence for data collection in settings without strong clinical trial infrastructure. At its core, this paper is about building equity in rare disease treatment and bringing meaningful solutions to underserved communities. We hope it sparks valuable conversations and inspires more action across the healthcare space.

What does the future hold for the healthcare sector? And how can foresight enable even more patient centric and value based healthcare? This will be the topic next week in Basel. Can't wait being part of a La Futura event again together with Nils Müller & Hanne Lindholt Caspersen. See you there, see you in the future.   

📑This Monday, February 12th, Inveniam members Albert Cot and Carla H. V. joined the Presentation of the 2023 BioRegion of Catalonia Report, a highlight of Barcelona health Innovation Week. The session spotlighted the latest trends in the life sciences and healthcare ecosystems, underlining the region’s leadership in these vital sectors. The report delves into the sector’s imminent 💻digital transformation, highlighting the essential role of integrating advanced technology and🧬 health data. It discusses the need to navigate regulatory challenges, adopt manufacturing advancements, and promote new therapeutic strategies, positioning itself as a must-read for stakeholders across the sector. 💡Moreover, the 2023 BioRegion Report showcases Catalonia’s significant contribution to the life sciences and healthcare sectors, marking it as a powerhouse of health innovation. It documents the region’s impressive growth in investments and innovation, establishing it as a key hub for digital health advancement and supportive environment for talent and infrastructure development. We invite industry professionals, investors, and policymakers to explore the report and seize the opportunities presented by Catalonia’s vibrant ecosystem https://report.biocat.cat (2023 BioRegion Report – The life sciences and healthcare sector in Catalonia (biocat.cat)) #BioRegion #BioRegionReport #BioCat #InveniamGroup #HealthcareInnovation # #BCNHealthInnovationWeek #LifeSciences 

Next week the LaFutura special edition: "Healthcare 2040 - the power of foresight" is taking place in Basel at the Novartis pavillion. 🚀I will be moderating the foresight panel, with panel participants: Adi Yoffe, Guido Beier and Ywan K.. 💫So what is foresight? You ask. Foresight is the capability to think about the future, to imagine possible outcomes and to make plans about how to get to the point on the horizon. It actually is a natural human ability, which we unfortunately dis-learn because of our upbringing and current thinking models. 🎇In this panel discussion we will be discussing how we perform foresight, how we do it differently (probably), which sectors or parts of organizations are making use of it for which purposes, and last but not least, who is really good at it, or making use of it with success. 🤩I am very much looking forwards to meeting all of you, and in particularly to this panel discussion, as well as all the other presentations and panel discussion. 🙏Particularly thanks to the brilliant Antonis Sarlikiotis for making it all possible in the Novartis Pavilion.

"Navigating the Microbial Frontier: Funding and Future of Healthcare Innovations | Ep 8 HeathTech Growth Podcast • Ever wondered how delving into the uncharted territory of microbes could reshape healthcare? • This episode is a treasure trove of insights for anyone looking to bridge the gap between complex scientific research and practical investor appeal." "Here’s what you’ll discover: 1. ⚖️ Balancing Scientific Evidence with Digestibility:  Simplify data, focusing on key statistics that highlight microbiology's impact, making the research accessible and compelling.  2. 👥 Expanding the Audience:  Reach beyond traditional scientific communities, engaging with life sciences enthusiasts and drug discovery advocates in non-clinical settings to broaden appeal and support. 3. 🔍 Narrowing the Focus:  Concentrate on microbiology's specific applications, like drug discovery, to clarify the mission and strengthen the message. 4. 🌱 Refreshing the Narrative:  Continuously update the story with new insights and developments, maintaining audience engagement and demonstrating ongoing value." "These strategies, emphasizing clear communication, audience expansion, focused messaging, and narrative updates, are vital for overcoming skepticism and advancing Ross's pioneering research in microbial dark matter." #microbiology #microbiome #molecules #discovery https://lnkd.in/gnrKAtsX

📸 Today, at the #EITHealthSummit ( 📍 Rotterdam), presenting the new operational plan for innovation access in the Catalan Health System. Auria Albacete, representing #Biocat, has moderated a panel in which different stakeholders have presented this ground-breaking initiative, with: 🗣️ Ramon Maspons Bosch | Catalan Ministry of Health 🗣️ Xavier Cos | Catalan Institute of Health 🗣️ Enrique Hernández | Loop Dx 💡 The speakers have emphasized how important the paradigm shift is: the system must be able to define and share its needs, so that #innovators will be able to develop targeted solutions for unmet clinical needs. It is also paramount, according to the experts, to focus on a value-based #healthcare approach, prioritizing the impact on patients beyond the cost of the product. 🧐 Read the plan: https://tuit.cat/ZayQi 👉 #Biocat led the subcommittee responsible for designing the actions included in the plan.

Can niche strategy work in a predominantly generic market What are the merits of pursuing a niche strategy? Part of the question here is whether it’s better to do very well in a small segment or struggle for share in a large portion of the market. There is often a pre-disposition towards larger patient populations. That said, specialty and rare disease products have proven that significant sales are possible in relatively small patient populations. So how do you make these types of tradeoff decisions? Check out the Solutions page of our website where discuss this topic and provide valuable insights on a wide range of topics. https://lnkd.in/eK2gMv3r #biotech #strategy #insight